Frontier IP Reports Widened Losses, Audit Concerns and Strategic Shift with Cambridge Innovation Hub

Separately, there is a material uncertainty related to going concern. Management’s three-year cash forecast showed insufficient cash to cover operating costs for the 12 months from signing. The Board plans to bridge this via a mix of new equity, borrowing and subleases of SC2. They “reasonably expect” funding to arrive and have prepared the accounts on a going concern basis, but timing and amount are not guaranteed. For investors, that is a clear risk flag: funding and SC2 commercialisation need to land.

Portfolio momentum in a lean market

Despite funding headwinds, several companies made good technical or commercial progress and raised money:

• 2D Photonics – raised €25 million for CamGraPhIC Srl, backed by CDP Venture Capital, Nato Innovation Fund, Sony Innovation Fund, Join Capital, Bosch Ventures and Indaco Ventures.
• GraphEnergyTech – £1 million round led by Aramco Ventures and a perovskite collaboration backed by nearly £900,000 from Innovate UK.
• Dekiln – £693,000 raised and first commercial installation post period end.
• Nandi Proteins – more than £500,000 via a convertible loan, with Nesta and Scottish Enterprise.
• Pulsiv – launched a 65W USB-C reference design at 96% efficiency and won the Power Sources Manufacturers Association’s first Global Energy Efficiency Award; post period end, a global stocking agreement with Farnell.
• The Vaccine Group – £1 million DEFRA grant for S. suis, an Innovate UK Smart Grant for bovine diseases and post period end “outstanding” cattle trial results for BRSV candidates.
• Alusid – two international distribution agreements during the year and a third post period end, plus Mas tiles launched via Topps Tiles.
• Amprologix – £740,000 pre-Series A post period end to take epidermicin NI01 through pre-clinical and into Phase I.

These updates do not immediately show up in cash or NAV growth, but they are useful signals of commercial traction and validation from credible partners.

Leadership changes

Two executive directors plan to depart: Chief Commercialisation Officer Matthew White and Chief Financial Officer Jo Stent. Both have extended timelines – currently to March and April 2026 respectively – so there is runway for handover, but investors should watch succession execution closely.

What I like vs what worries me

Positives

• SC2 could create a recurring income stream, deepen deal flow and speed portfolio execution by co-locating teams.
• Equity portfolio value held broadly steady at £33.4 million despite market drag.
• High-quality third-party validation across the portfolio – Nato Innovation Fund, Sony, Bosch Ventures, Aramco Ventures, DEFRA, Innovate UK and Topps Tiles.
• Operating expenses modestly reduced despite inflationary pressure.

Negatives

• Qualified audit opinion on Stage 2 valuations – this needs resolution.
• Material uncertainty over going concern – the plan relies on funding and SC2 subletting.
• NAV per share down to 61.0p, with all KPIs/APMs missed in the year.
• Large right-of-use lease and long commitment – execution risk if subletting lags.
• Leadership churn – succession for the CFO and CCO must be handled cleanly.

Jargon buster

• Unrealised loss – a paper loss from marking investments to estimated fair value, not a cash loss from selling.
• NAV per share – net assets divided by shares outstanding; a simple yardstick for balance sheet value.
• IFRS 16 lease accounting – brings long leases onto the balance sheet as assets and liabilities; it is not an upfront cash spend.

What to watch over the next 12 months

• SC2 execution – sublease occupancy, pricing and timing of rental inflows.
• Funding actions – any equity raise or borrowing to address the going concern uncertainty.
• Realisation progress – any disposals or liquidity events to recycle capital and validate valuations.
• Audit issues – movement on Stage 2 valuation evidence and overall audit status at the interim and next full year.
• Portfolio catalysts – 2D Photonics development, Pulsiv customer wins, TVG partnering, Alusid distribution traction, and Amprologix clinical steps.
• Succession – appointments and transition plans for the CFO and CCO roles.

Bottom line

This is a mixed update. Operationally, the portfolio is getting meaningful third-party backing and technical wins. Strategically, SC2 could be transformative if Frontier IP fills the space and turns it into steady cash. Financially, the step up in losses, qualified audit opinion and going concern uncertainty are clear red flags that put execution front and centre. If management delivers on funding and SC2 occupancy while landing one or two exits, sentiment could swing – but until then, risk remains elevated.